MDL | MFCD20272929 |
---|---|
Molecular Weight | 503.48 |
Molecular Formula | C26H20F3N7O |
SMILES | CC1=CC=C(C=C1NC2=NC(C3=CC=CN=C3)=NC4=C2C=NN4C)C(NC5=CC=CC(C(F)(F)F)=C5)=O |
IC50: 3.3 nM (EphA2), 3 nM (EphB4) [2] .
NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity. The data suggests a close cross talk between the VEGFR and EphR signaling during vessel formation [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NVP-BHG712 (3, 10 and 30 mg/kg, p.o., daily) inhibits VEGF driven tissue growth and angiogenesis [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Mice arrying chambers [1] . |
Dosage: | 3, 10 and 30 mg/kg. |
Administration: | P.O. daily for 4 days. |
Result: | Significantly inhibited VEGF stimulated tissue formation and vascularization at doses of daily 3 mg/kg. Administration of 10 mg/kg/kg p.o. was sufficient to reverse VEGF enhanced tissue formation and vessel growth. |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 31.25 mg/mL ( 62.07 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.9862 mL | 9.9309 mL | 19.8618 mL |
5 mM | 0.3972 mL | 1.9862 mL | 3.9724 mL |
10 mM | 0.1986 mL | 0.9931 mL | 1.9862 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.13 mM); Clear solution